Treatment of hepatcellular carcinoma with neoplastic thrombosis of the main portal vein using sorafenib and percutaneous radiofrequency ablation comparing to Sorafenib alone

Not Applicable

Completed

• Conditions: Hepatocellular carcinoma in cirrhosis; Hepatocellular carcinoma; Cancer

• Registration Number: ISRCTN95691970
• Lead Sponsor: D. Cotugno Hospital

Brief Summary

2016 results in: https://www.ncbi.nlm.nih.gov/pubmed/27793949

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2014-06-04
• Study Start: 2016-07-26
• Last Update Posted: 4 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Child-Pugh A 5-6 liver cirrhosis
2. A single HCC nodule < 6.5 cm in diameter and concomitant main portal vein tumor thrombus (MPVTT)
3. Maximum 3 HCC nodules with the largest one no more than 5 cm with MPVTT

Exclusion Criteria

1. Patients with ascites
2. Patients with bilirubin >2 mg/dl
3. Patients and with extrahepatic spread of disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The survival rate, expressed in months, after 12, 24 and 36 months from treatment.